- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.06. | Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules | ||
| 27.06. | Supreme Court upholds ACA preventive services mandate | ||
| 27.06. | Congress should reconsider breaking up PBMs, experts say | ||
| 26.06. | RFK Jr.-appointed panel recommends flu shots be free of contested preservative | ||
| 26.06. | Vor, with new CEO, changes course to target autoimmune disease | ||
| 26.06. | Acadia's 'very bullish' sales forecast restores some confidence on Wall Street | ||
| 26.06. | Incyte replaces CEO Hoppenot with dealmaker Meury | ||
| 26.06. | Recast CDC panel recommends new RSV antibody for infants | ||
| 26.06. | CDC panel, newly remade by RFK Jr., questions vaccine evidence | ||
| 25.06. | Kymera adds Gilead as research partner, while advancing new candidate with Sanofi | ||
| 25.06. | FDA investigating Elevidys safety; Nektar shares spike on eczema data | ||
| 24.06. | Lexeo to help launch spinout around RNA drugs for the heart | ||
| 24.06. | Cassidy calls for delay to CDC vaccine meeting, challenging RFK Jr. | ||
| 24.06. | New Amgen obesity drug data disappoint Wall Street | ||
| 24.06. | Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug | ||
| 23.06. | Relentless innovation: Bold exploration in advancing therapeutic options for every patient, every discovery | ||
| 23.06. | Top drug official at FDA reportedly set to exit next month | ||
| 23.06. | Cidara stock soars as antiviral drug succeeds in flu study | ||
| 23.06. | Illumina to buy SomaLogic in deal worth up to $425M | ||
| 23.06. | Novo abruptly ends obesity drug deal with Hims | ||
| 23.06. | Compass' big psychedelic study doesn't impress investors | ||
| 23.06. | [Podcast] Trial Trailblazers: Behind clinical breakthroughs | ||
| 23.06. | The rise of GLP-1 drugs: Transforming weight loss treatment | ||
| 20.06. | Prothena to lay off majority of staff; Zealand shares obesity drug data | ||
| 20.06. | A longer 'winter': Public funding slowdown heightens pressure on biotech startups |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .